新闻（News）

文章类型：

• 新闻（News）
  

说明：

• 对于会议或者研究发布的重要研究信息的快速报道。
• 新闻主要是快速传播研究的信息，提供重要文献的原理、数据和结果。不做或者只加极简短的评论。可以有简短的对文章作者的Q&A。
• 选择较高级别证据相关的消息和正在进行的重要临床试验的信息。
• 新闻文章将链接至相关的发表的文章或者信息源。
  

稿件来源：

• 邀请
• 欢迎加入传播新知识的队伍
  

写作要求：

• 字数：500-1000，不包括标题，摘要
• 来源文献：标准参考文献格式加网址链接
• 文字简练
• 建议包括以下几个方面内容：
  1）时间、地点、人物（研究时间，研究者，研究单位和公司）
  2）信息来源（哪个杂志报道，写明期别，页码和作者，FDA等机构）
  3）研究的目标、方法、结果和结论。
  4）小结
  

NATURE的方式的HIGHLIGHTS。
有一定的新闻方式。其实也许并没有采访本人，只是摘要了有关的句子。

还配上图片，可能根本无关的图片，或者是作者 的国家相关的图片。

NELSON shows less is more in lung cancer screening

Low-dose CT screening has beenrecommended for asymptomaticsmokers and ex-smokers at highrisk of developing lung cancer.
Although a high proportionof those screened will havepulmonary nodules detected, onlya small percentage will have lungcancer. Raising the threshold forscreening to avoid unnecessaryCT scans is obviously attractive;however, the sensitivity to detectcancer might be decreased, leading to increased mortality.
Now, results from two publishedarticles covering the NELSONtrial, led by Nanda Horeweg,have addressed three unansweredquestions: feasibility of screeningintervals longer than 1 year, a twostepnodule-management strategy,and the use of cancer volume. “Weconsidered it important to developa screening strategy and a nodulemanagement protocol with optimaldetection of lung cancer andminimal numbers of CT scans,and invasive diagnostic proceduresrequired to distinguish malignantfrom benign nodules,” explains Horeweg. The study included7,155 participants and showedthat small nodules (<100 mm3or <5 mm diameter) are notpredictive of cancer development.Immediate diagnostic evaluationis necessary for large nodules(≥300 mm3 or ≥10 mm diameter).Volume doubling time assessmentis advocated only for intermediatesizednodules (100–300 mm3 ordiameter 5–10 mm).
Crucially, “this is the first studyto use lung cancer probabilityof the individual to design newnodule-management protocolsand evaluate the performanceof the new protocols in terms ofsensitivity, specificity, predictivevalues and number of requiredadditional diagnostic procedures,and to compare the new protocolto the current standard ofpractice,” says Horeweg.
Lung cancer screening inthe NELSON trial yielded highspecificity and sensitivity, withonly a small number of intervalcancers. Moreover, the diseasestagedistribution of the lungcancers in this trial was asfavourable as the results observedin the US National Lung ScreeningTrial, which demonstrated a 20%lung cancer mortality reductionby low-dose CT screening. Nextsteps for the NELSON teaminclude “comparisons betweenthe two study groups to determinelow-dose CT screening onhealth-care utilization, costsand overdiagnosis.”

Lisa Hutchinson

Original articles Horeweg, N. et al. Lungcancer probablity in patients with CT-detectedpulmonary nodules: a prespecified analysisof data from the NELSON trial of low-doseCT screening. Lancet Oncol. doi:10.1016/S1470-2045(14)70389-4 | Horeweg, N. et al.Detection of lung cancer through low-dose CTscreening (NELSON): a prespecified analysisof screening test performance and intervalcancers. Lancet Oncol. doi:10.1016/S1470-2045(14)70387-0

Burki T. Cancer survivors continue to smoke. Lancet Oncol. 2014 Sep;15(10):e423. doi: 10.1016/s1470-2045(14)70393-6. PMID: 25328950.



报道以下文章：
Cancer Epidemiol Biomarkers Prev 2014; published online Aug 6. http://cebp.aacrjournals.org/ lookup/doi/10.1158/1055-9965. EPI-14-0046

---

报道来自JAMA的文章。这样的新闻往往涉及政策，经济学等。

---

报道来自美国CDC的最新电子烟和常规烟草流行病学信息。报道篇幅较大。起到对于分析和传播国家CDC信息的作用。

---

报道 发表于BMJ的临床研究 Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study | The BMJ

Efficacy of TILs confirmed
来自nature reviews clinical oncology，报道了《新英格兰医学杂志》中一篇晚期恶性黑色素瘤TIL治疗进展的研究。



Comment on

• Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG.N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233.PMID: 36477031 Clinical Trial.
  

---

简要报道了达可替尼和ARCHER研究。

---

张嘉涛， 钟文昭. 阿来替尼新辅助治疗ALK 阳性Ⅱ~Ⅲ期非小细胞肺癌患者：评NAUTIKA1伞式研究. 循证医学2023年第23卷第1期
《循证医学》杂志的循证评价，这种情况仅限于获得原作者授权。应尽量压缩有关的内容，并且不能直接使用未经授权的图片和表格。

推荐的新闻报道形式。
以尽量简洁的形式报告研究的目标，方法，核心数据和结论。可加简洁的推荐性的文字。
提供研究发表的链接。

Taylor R. Perioperative chemotherapy for gastro-oesophageal cancer. Lancet Oncol. 2006 Aug;7(8):624. doi: 10.1016/s1470-2045(06)70783-5. PMID: 16903011.

Bartlett S. Predictive model for hereditary colorectal cancer. Lancet Oncol. 2006 Aug;7(8):624. doi: 10.1016/s1470-2045(06)70782-3. PMID: 16900599.

Alectinib superior to chemotherapy in advanced ALK+ NSCLC
The Lancet Oncology 19 (6), e285, 2018

Alectinib is more effective than standard chemotherapy in patients with advanced or metastatic anaplastic lymphoma kinase (ALK)- positive nonsmall-cell lung cancer (NSCLC) who have progressed on —or are intolerant to—crizotinib, according to a recent study. In the phase 3 ALUR trial, Silvia Novello (University of Turin, Turin, Italy) and colleagues enrolled 120 patients across 13 countries in Europe and Asia with histologically or cytologically confirmed advanced, recurrent, or metastatic ALK-positive NSCLC, who had received previous treatment with platinum-based doublet chemotherapy and crizotinib. 107 patients were randomised (2: 1) to receive alectinib (600 mg twice daily; n= 72) or chemotherapy (pemetrexed 500 mg/m² or docetaxel 75 mg/m², every 3 weeks; n= 35) until disease progression, withdrawal, or death. The primary endpoint was progression-free survival in the intention-to-treat population; a key secondary endpoint was CNS objective responses in patients with measurable baseline CNS disease. Investigator-assessed median progression-free survival was significantly longer with alectinib than with chemotherapy (9· 6 months [95% CI 6· 9–12· 2] vs 1· 4 months [1· 3–1· 6], hazard ratio [HR] 0· 15; 95% CI 0· 08–0· 29, p< 0· 001). Independent review committee-assessed progression- free survival was consistent with these findings. In patients with measurable baseline CNS disease, a significantly larger proportion achieved an objective CNS response with alectinib (13 [54%] of 24) than with chemotherapy (0 of 16; p< 0· 001). Alectinib also had a favourable safety profile: grade 3 or worse adverse events occurred in 19 (27%) of 70 patients in the alectinib group versus 14 (41%) of 34 in the chemotherapy group.
“Although for first-line treatment of advanced ALK-positive lung cancer alectinib was recently shown to be superior to the old standard crizotinib... a direct comparison with chemotherapy was missing so far,” explained coauthor Jürgen Wolf (University Hospital Cologne, Cologne, Germany).“The ALUR trial now shows a significantly better progression-free survival, CNS efficacy, and tolerability compared to chemotherapy in chemotherapy and crizotinib-pretreated patients.”“We will always need chemotherapy,” commented David Ross Camidge (University of Colorado Denver, Denver, CO, USA),“but the more we understand about a cancer and can target its biology directly, the more we can put off the less personalised, scatter-gun approaches to treatment until later and as later lines of defence.”